Abstract
Medications such as ß-blockers are currently the primary treatment for patients with hereditary arrhythmia syndromes such as long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). However, these drugs are ineffective in some patients, and the other treatment option, that is implantable cardioverter defibrillator (ICD) implantation, is associated with significant complications in young and active patients. Left cardiac sympathetic denervation (LCSD) may reduce the wide gap between life-long ß-blocker medication and ICD implantation. Although LCSD is highly effective in prevention of cardiac events in patients with LQTS and CPVT, it is rarely used. The recently introduced procedure video-assisted thoracoscopic LCSD is associated with short hospital stays and low morbidity. Thus, LCSD is an important therapeutic option for patients with LQTS and CPVT.